Read more to answer the following questions:
1. What is the optimal specimen for molecular testing?
2. Should testing for ALK translocation be conducted?
3. What is the optimal first line therapy for ALK-translocated lung cancer?
Welcome to Molecular Oncology Tumor Boards
The Molecular Oncology Tumor Boards are a series of bi-monthly, user-driven discussions designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies. Moderated by an expert pathologist and medical oncologist, each case will be updated with new information over a 2-week period as user comments are added. Sign in with your ASCO username and password to participate. After 2 weeks, the discussion will be locked to further commentary and users will be able to claim CME credit for their participation. Visit ASCO University to learn more.
To participate in discussions on other oncology-related topics, visit ASCO’s member community on myConnection. Connect with colleagues, build your professional network, exchange ideas, collaborate, and more
Molecular Oncology Tumor Board
ASCO University
Apr 11, 2018 9:13 AM
15 Comments
Molecular Oncology Tumor Board
ASCO University
Feb 14, 2018 7:40 AM
Read more to answer the following questions:
1. Review two different screening tests for Lynch Syndrome
2. Recognize the actions needed to identify lynch syndrome
3. Explain the therapeutic importance of microsatellite instability in patients with metastatic colorectal cancer
1. Review two different screening tests for Lynch Syndrome
2. Recognize the actions needed to identify lynch syndrome
3. Explain the therapeutic importance of microsatellite instability in patients with metastatic colorectal cancer
Molecular Oncology Tumor Board
ASCO University
Dec 06, 2017 10:09 AM
Read more to answer the following questions:
1. What are conceivable next steps in managing this patient?
2. How does the molecular biology of mucosal melanoma vary from cutaneous melanoma?
3. What factors would guide subsequent treatment options?
1. What are conceivable next steps in managing this patient?
2. How does the molecular biology of mucosal melanoma vary from cutaneous melanoma?
3. What factors would guide subsequent treatment options?
Molecular Oncology Tumor Board
ASCO University
Nov 08, 2017 8:58 AM
Read more to answer the following questions:
1. What additional testing should the patient undergo?
2. Will the results of genetic testing help guide prognosis in this patient?
3. Will the results of genetic testing help determine what treatment would work best for the patient?
1. What additional testing should the patient undergo?
2. Will the results of genetic testing help guide prognosis in this patient?
3. Will the results of genetic testing help determine what treatment would work best for the patient?
Molecular Oncology Tumor Board
ASCO University
Oct 11, 2017 9:00 AM
Read more to answer the following questions:
1. Describe patterns of response and progression in metastatic castration resistant prostate cancer
2. Discuss common molecular alterations in prostate cancer
3. Recognize conditions in which immunotherapy is a treatment option in prostate cancer
1. Describe patterns of response and progression in metastatic castration resistant prostate cancer
2. Discuss common molecular alterations in prostate cancer
3. Recognize conditions in which immunotherapy is a treatment option in prostate cancer
Pages
Advertisement